7月10日，中国疾控中心最新发布的《全国急性呼吸道传染病哨点监测情况》显示，呼吸道合胞病毒 （RSV）在住院严重急性呼吸道感染病例呼吸道样本检测阳性率中排在首位。回溯监测周期，2025年第 4周至27周（1月底至7月初），呼吸道合胞病毒始终稳居住院严重急性呼吸道感染病例呼吸道样本检测 阳性率前三甲，长期处于持续流行状态。 鲍亮表示，呼吸道合胞病毒预防单抗的防护周期约为5-6个月，刚好能覆盖一个完整的流行季，正是将 防与治衔接起来的具体实践。2024年的流行季，湖北省妇幼保健院已为近300名婴儿注射了预防单抗， 从实际效果来看，它能有效帮助孩子抵御RSV感染。 除了通过医学上的预防手段外，印根权还建议，要增强孩子自身抵抗力，需要为孩子提供正确的护理、 全面的营养，让孩子进行适当锻炼，拥有愉快的心情，这才是增加抵抗力最好的"药"。 新京报记者 张兆慧 校对 卢茜 对此，广州市妇女儿童医疗中心柳州医院党委副书记、执行院长，广州市妇女儿童医疗中心内科部副主 任、呼吸科病区主任印根权建议，应高度重视呼吸道合胞病毒的预防工作，将健康教育、免疫预防等公 共卫生措施深度融入医疗服务全过程，从源头降低婴儿重症病例的发生风险。 ...

2025.06. 24 本文字数：2380，阅读时长大约4分钟 作者 | 第一财经 林志吟 根据中国疾控最新发布的全国急性呼吸道传染病哨点监测情况，第24周（2025年6月9日—6月15 日），住院严重急性呼吸道感染病例呼吸道样本检测阳性率前三位病原体中，呼吸道合胞病毒 （RSV）赫赫在列。 病毒危害 呼吸道合胞病毒是一种常见的呼吸道病毒，主要通过呼吸道飞沫与密切接触传播。 深圳市妇幼保健院新生儿科主任杨传忠对第一财经记者表示，呼吸道合胞病毒感染以呼吸道症状为 主，临床典型表现为喘息、喘憋（呼吸困难），属于喘息性支气管炎范畴，部分患儿可伴发热，严重 者可能出现呼吸衰竭、心功能衰竭等危及生命的并发症。 尽管任何年龄段人群均可能感染呼吸道合胞病毒，但其在婴儿，特别是早产儿、患有慢性肺病或先天 性心脏病的儿童以及老人中，病情通常更为严重。 "早产儿由于器官发育不完善，感染呼吸道合胞病毒后风险更高，例如，32周到40周是肺泡快速发 育阶段（每日新增约20万到30万个肺泡），而早产儿肺泡数量不足、功能不成熟，感染后易引发呼 吸衰竭，需呼吸机支持，甚至继发心力衰竭。"杨传忠说，足月儿因肺泡发育完整，感染后耐受性更 强，6 ...

Core Insights - The article discusses the seasonal variation of Respiratory Syncytial Virus (RSV) in different provinces of China, highlighting that the northern regions experience a peak season from November to April, while southern regions have sporadic cases throughout the year [1][2][6] Group 1: RSV Prevalence and Impact - RSV is one of the most common pathogens causing respiratory infections in children under five globally, with a significant presence in severe acute respiratory infection cases in China [1][4] - The positive detection rate of RSV in hospitalized severe acute respiratory infection cases has consistently ranked among the top three pathogens since the fourth week of 2025 [1][2] - The virus primarily spreads through respiratory droplets and close contact, with severe cases leading to respiratory failure and heart failure, particularly in infants and vulnerable populations [4][5] Group 2: Prevention Strategies - Although no RSV vaccine has been approved in China, preventive monoclonal antibodies are available, and the long-acting monoclonal antibody Nirsevimab has been approved for use in newborns and infants [5][6] - A successful case from Galicia, Spain, showed that the introduction of preventive monoclonal antibodies into the immunization program led to an 89% reduction in RSV-related hospitalizations [6] - The article emphasizes the need for tailored prevention strategies based on regional RSV patterns, with ongoing discussions about vaccination guidelines for subtropical regions like Guangdong [7][8] Group 3: Future Considerations - There are concerns regarding the long-term effects of monoclonal antibody administration on the immune system of infants, with initial observations indicating no significant increase in RSV infections later in life [9] - The economic implications of frequent vaccinations in regions without a clear RSV season are also under consideration, as the cost-effectiveness of such strategies remains to be evaluated [7][8]